Peter Ordentlich

Founder at SYNDAX PHARMACEUTICALS, INC.

57 year

Consumer Services

Health Technology

Commercial Services

Profile

Peter Ordentlich is the founder of Syndax Pharmaceuticals, Inc. since 2005, serving as Chief Scientific Officer.
Former positions include Principal at The Salk Institute for Biological Studies and Research Scientist at X-Ceptor Therapeutics, Inc. Education includes undergraduate and doctorate degrees from the University of Pennsylvania.

Peter Ordentlich active positions

Companies	Position	Start
SYNDAX PHARMACEUTICALS, INC.	Founder	2005-10-10

All active positions of Peter Ordentlich

Former positions of Peter Ordentlich

Companies	Position	End
X-Ceptor Therapeutics, Inc. X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development of small molecule therapeutics	Corporate Officer/Principal	-
The Salk Institute for Biological Studies The Salk Institute for Biological Studies Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	-

See the detail of Peter Ordentlich's experience

Training of Peter Ordentlich

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Ordentlich's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
The Salk Institute for Biological Studies The Salk Institute for Biological Studies Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company	Health Technology
University of Pennsylvania University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
X-Ceptor Therapeutics, Inc. X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development of small molecule therapeutics	Commercial Services